Related Experiment Videos
Cefotetan: comparative study in vitro against 226 Gram-negative clinical isolates
The Journal of Antimicrobial Chemotherapy
|January 1, 1983
Summary
The new cephamycin, cefotetan, shows potent in vitro activity against Gram-negative pathogens, often exceeding older cephalosporins. Cefotetan demonstrates comparable efficacy to cefotaxime against Enterobacteriaceae, with notable exceptions.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- The emergence of antibiotic resistance necessitates the development of new antimicrobial agents.
- Cephamycins represent a class of beta-lactam antibiotics with broad-spectrum activity.
Purpose of the Study:
- To evaluate the in vitro antimicrobial activity of cefotetan against recently isolated Gram-negative pathogens.
- To compare cefotetan's efficacy with established cephalosporins: cephalothin, cefoxitin, cefuroxime, and cefotaxime.
Main Methods:
- In vitro susceptibility testing of 226 Gram-negative bacterial isolates (Enterobacteriaceae and Acinetobacter).
- Determination of minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs).
- Evaluation of inoculum effect on cefotetan's MIC.
Main Results:
- Cefotetan exhibited greater potency than cephalothin, cefoxitin, and cefuroxime against most tested pathogens.
- Cefotetan and cefotaxime showed similar activity against Enterobacteriaceae, except for Enterobacter spp., which were more susceptible to cefotaxime.
- Cefotaxime demonstrated the best activity against Acinetobacter, though overall activity against this genus was limited.
Conclusions:
- Cefotetan is a potent new cephamycin with significant in vitro activity against Gram-negative bacteria.
- Cefotetan demonstrates promising efficacy, comparable to cefotaxime against many Enterobacteriaceae, warranting further clinical investigation.